HOME >> BIOLOGY >> NEWS
Novel therapeutic bortezomib moves to phase II trial in lung cancer patients

(NEW ORLEANS) -- A three-drug combination including the novel molecularly targeted agent bortezomib, the first drug in its class, proved well-tolerated and showed promising efficacy in patients with advanced non-small cell lung cancer, according to phase I trial results reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

The triple-therapy regimen will now be tested nationally in a phase II trial as first-line therapy for advanced non-small cell lung cancer. Angela Davies, assistant professor of hematology/oncology and principal investigator of the phase I trial, will lead the phase II trial as well.

The regimen consists of bortezomib, gemcitabine and carboplatin. Gemcitabine and carboplatin represent an accepted first-line treatment combination for advanced non-small cell lung cancer.

In the small phase I trial, the three drugs were administered on a similar schedule. Out of 12 patients, four had a partial response and seven had stable disease.

In the larger phase II trial, which will enroll 99 patients, the drugs will be given sequentially, with bortezomib following the chemotherapy drugs. Preclinical research at UC Davis Cancer Center suggests that giving bortezomib last may be more effective than giving it first or at the same time.

Bortezomib is a proteasome inhibitor that blocks the signals cancer cells rely on to degrade cellular proteins. The result is a buildup of proteins that hastens cell death.

Bortezomib has been approved by the Food and Drug Administration for the treatment of multiple myeloma, but had not been tested before in non-small cell lung cancer.

"Bortezomib is an exciting therapeutic, and we're encouraged that we've been able to take this promising three-drug combination immediately from phase I to phase II," Davies said.

Of the estimated 175,000 new cases of lung cancer diagnosed in the United States each year, nearly 80 percent are n
'"/>

Contact: Claudia Morain
530-219-5053
University of California, Davis - Health System
5-Jun-2004


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel approaches to current cellular therapies continue progress toward disease prevention
3. Novel therapies show promise against myeloid leukemia
4. Novel sensors help clear the air
5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
8. Novel bacterium detoxifies chlorinated pollutants
9. Novel flu vaccine shows promise in mice
10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
11. Novel method identifies hidden genes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2019)... ... January 07, 2019 , ... Sonion ... for hearing instruments and specialty earphones, and Valencell , the leading innovator ... receiver in canal with an embedded biometric sensor. The BiometRIC measures key vital ...
(Date:1/4/2019)... ... January 03, 2019 , ... Over the last few ... drug discovery research workflows with biology ranging from single cell-type spheroids to highly ... vitro studies, they create several challenges that need to be overcome in order ...
(Date:12/22/2018)... ... December 21, 2018 , ... On Wednesday, Dec. ... Healthcare Drinks event featuring Helen Chen, Greater China Managing Partner of L.E.K. Chen ... was moderated by patent attorney David J. Dykeman , co-chair of Greenberg ...
Breaking Biology News(10 mins):
(Date:12/18/2018)... ... December 18, 2018 , ... USDM Life Sciences, the leading ... industry, unveiled a completely redesigned website at http://www.usdm.com . The site offers ... their valued clients and business partners. , The website has a revamped ...
(Date:12/13/2018)... ... December 12, 2018 , ... Helping conclude Healthy Aging Month this ... slim hearing aid within its Vision and Hearing campaign that sets out to shed ... show that despite continued efforts to destigmatize hearing aids over the years, 9 out ...
(Date:12/5/2018)... ... December 05, 2018 , ... STRmix™ – sophisticated forensic ... interpret – has been used to convict a Wyoming man of third-degree sexual assault, ... Laboratory used STRmix™ to test for DNA on the couch cushions on which the ...
(Date:11/26/2018)... ... 26, 2018 , ... USARAD Holdings Inc., the leading US ... (Virtual Radiologic founders) among other healthcare investors exhibits at the Radiological Society of ... Chicago. The company is proud to announce a 10 year anniversary since its ...
Breaking Biology Technology:
Cached News: